Simplified Chinese
scroll down
PRODUCTS
Product Series
Eleven products have obtained drug registration approvals and been authorized for emergency use, including the following core products:
- The world’s first dual‑carrier 13‑valent pneumococcal polysaccharide conjugate vaccine
- China’s first quadrivalent lyophilized human rabies vaccine (human diploid cell–derived)
- China’s first acellular DPT–Haemophilus influenzae type b combination vaccine (quadrivalent vaccine)
- World’s first 60 µg hepatitis B vaccine
GLOBAL PRESENCE
Global Presence
We will uphold the dual approach of “bringing in” and “going out,” steadily expand in-depth cooperation with international pharmaceutical companies, and continuously strengthen Kangtai’s global footprint across key target regions.
International Cooperation
NEWS
News and Information
Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.
2026-07-15
Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.
Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.
2026-07-09
Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.
The company’s internal publication, “Minhai People”
2026-05-12
1. On a computer, open this link https://flbook.com.cn/c/wIYHOIyHaZ to view the desktop display. 2. Use WeChat to scan the QR code in the attachment to view the mobile display.
Reposted: Kangtai Biological attends the 2026 Vaccine and Health Conference; several innovative vaccine candidates have drawn significant attention from the industry.
2026-04-22
Recently, the 2026 Vaccine and Health Conference, hosted by the Chinese Society of Preventive Medicine, was held in Changsha, Hunan Province. The conference focused on key topics such as cutting-edge vaccine technologies, the current state of disease prevention and control, and the development of next-generation vaccines. It brought together industry experts to share the latest research findings, build consensus on industry development, and support advancements in China’s vaccine R&D, clinical application, and vaccination service delivery. During a special session on “Advances in Polysaccharide–Protein Conjugation Technology and Its Vaccine Applications,” industry experts highlighted that, compared with other carrier‑protein‑based vaccines, the dual‑carrier PCV13 (TT/DT) offers distinct advantages: it not only boasts five-year data demonstrating robust immune persistence in the domestic population, but also…
The 2026 Kangtai Biological Supplier Conference was successfully held, with the company joining forces with its partners to chart a new course for high-quality development.
2026-03-24
On March 20, 2026, Kantai Biologics held its 2026 Supplier Conference at Beijing Minhai Biotechnology Co., Ltd., a wholly owned subsidiary of Kantai Biologics, under the theme “Breaking Barriers, Seizing Opportunities, and Achieving Win-Win Collaboration.” The event brought together core supplier representatives from across the country to engage in in-depth discussions on industry development trends and ways to deepen strategic partnerships, working together to lay a solid foundation for the high-quality growth of the biopharmaceutical sector. As the biopharmaceutical industry accelerates its pace of innovation, it faces both challenges and opportunities; amid these changes lies the potential for a new wave of industrial upgrading. In his address, Mr. Du Weimin, Chairman of Kantai Biologics, emphasized: “A stable supply chain…”
Deepening Government–Enterprise Communication to Boost Industrial Development — Ai Li, Secretary of the Party Group and Director of the Standing Committee of the Daxing District People’s Congress, Led a Research Visit to Minhai Biotechnology.
2026-03-13
On the morning of March 12, 2026, Ai Li, Party Secretary and Director of the Standing Committee of the District People’s Congress, led a delegation to the Daxing Biomedical Base. The group conducted an on-site visit and research at Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as Minhai Bio), listened to the company’s development needs, and provided support for its high-quality growth. Accompanying the delegation were Gao Dongmei, Member of the Party Leadership Group and Director of the Office of the District People’s Congress Standing Committee; Li Hong, Party Secretary and Director of the District Finance Bureau; and Sun Luofu, Party Secretary and Director of the District Industrial Promotion Center. Upon arriving at Minhai Bio, the delegation inspected the company’s production and R&D operations and gained a detailed understanding of its latest achievements in vaccine development, manufacturing processes, international cooperation, and other areas.
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%